<DOC>
	<DOCNO>NCT00005052</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . It yet know whether vaccine therapy effective observation alone melanoma . PURPOSE : This randomized phase III trial study vaccine therapy see well work compare observation alone treat patient primary stage II melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Primary Stage II Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect immunization GM2-KLH QS21 observation disease-free survival patient primary cutaneous stage II melanoma adequate surgery . - Determine overall survival toxicity two treatment arm . OUTLINE : This randomize , open-label , parallel , multicenter study . Patients stratify accord participate center , tumor thickness ( great 1.5 3.0 mm v great 3.0 4.0 mm v great 4.0 mm ) , gender , ulceration ( yes v ) , presence additional staging procedure regional lymph node ( yes v ) . Patients randomize one two arm . - Arm I : Patients vaccinate GM2-KLH QS21 subcutaneously day 1 week 1-4 , 12 , 24 , 36 , 48 , 60 , 72 , 84 , 96 , 120 , 144 total 14 vaccination . - Arm II : Patients undergo observation . Patients follow every 6 month 7 year . PROJECTED ACCRUAL : A total 1300 patient ( 650 per arm ) accrue study within 36 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary stage II melanoma great 1.5 mm without evidence lymph node metastases T3 T4 , N0 , M0 Must originate skin Wide excision minimum 12 cm margin surround primary lesion biopsy scar No 56 day since definitive surgical treatment ( wide excision ) No 12 week since primary surgery No clinical , radiological , pathological evidence incompletely resected disease , lymph node metastasis , intransit metastasis , distant metastatic disease PATIENT CHARACTERISTICS : Age : 18 80 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.8 g/dL Hepatic : SGOT/SGPT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN LDH great 2 time ULN Bilirubin great 2 time ULN Hepatitis B C negative Renal : Creatinine normal Other : Not pregnant nursing Negative pregnancy test No prior concurrent cancer except carcinoma situ cervix basal squamous cell skin cancer No autoimmune disorder No condition require systemic treatment immunosuppressive drug include treatment systemic corticosteroid No history CNS demyelinate inflammatory disease No hereditary acquire peripheral neuropathy No significant medical surgical condition psychiatric disorder require medication would preclude study No history severe allergic reaction shellfish HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy No concurrent biologic therapy Chemotherapy : No prior systemic chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy : No concurrent hormonal therapy except replacement therapy No concurrent corticosteroids No concurrent chronic systemic steroid Radiotherapy : No prior adjuvant radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : No prior preoperative infusion perfusion therapy No concurrent immunosuppressive medication No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>stage II melanoma</keyword>
</DOC>